Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 172

Sort by

Sort Order Select

Journal Articles

Clonal architecture and growth dynamics of ibrutinib-resistant CLL: Oligoclonal BTK/PLCG2 mutations and emerging non-BTK/PLCG2 drivers

Chingiz Underbayev, Bharath Dileep Kumar, Rohan Herur, Jonathan Chen, Hailey Harris, Lauren Vaughn, Victoria Rogness, Pia Nierman, Laura Samples, Adrian Wiestner

Blood (2025) 146 (Supplement 1): 5654.

https://doi.org/10.1182/blood-2025-5654

Published: 2025

Journal Articles

Role of the immune microenvironment in the clonal evolution of chronic lymphocytic leukemia

Victoria Rogness, Bharath Dileep Kumar, Chingiz Underbayev, Pia Nierman, Clare Sun, Christine Gruessner, Adrian Wiestner

Blood (2025) 146 (Supplement 1): 5653.

https://doi.org/10.1182/blood-2025-5653

Published: 2025

Journal Articles

BTK inhibition drives mobilization and compartmental shifts of CLL subclones

Christine Gruessner, Victoria Rogness, Bharath Dileep Kumar, Rohan Herur, Laura Samples, Clare Sun, Lita Freeman, Pia Nierman, Chingiz Underbayev, Adrian Wiestner

Blood (2025) 146 (Supplement 1): 7406.

https://doi.org/10.1182/blood-2025-7406

Published: 2025

Journal Articles

Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies

Blood (2025) 146 (Supplement 1): 245.

https://doi.org/10.1182/blood-2025-245

Published: 2025

Journal Articles

Loss-of-function alterations in TRAF3 drive BTK/PLCG2-independent ibrutinib resistance in CLL

Bharath Dileep Kumar, Rohan Herur, Victoria Rogness, Chingiz Underbayev, Adrian Wiestner

Blood (2025) 146 (Supplement 1): 434.

https://doi.org/10.1182/blood-2025-434

Published: 2025

Journal Articles

Venetoclax enhances T cell fitness and CAR T-cell manufacturing potential in chronic lymphocytic leukemia (CLL)

Arun Arunachalam, Beatriz Coutinho De Oliveira, Celine Gregoire, Ziran Zhao, Lily Simpson-Heavey, John Molina, Arnon Kater, Fleur Peters, Adrian Wiestner, Jennifer Woyach, J. Joseph Melenhorst

Blood (2025) 146 (Supplement 1): 2322.

https://doi.org/10.1182/blood-2025-2322

Published: 2025

Journal Articles

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells

Blood (2025) 145 (12): 1309–1320.

https://doi.org/10.1182/blood.2024024846

Published: 2025

Includes: Supplemental data

Journal Articles

Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK C481S -Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4610.

https://doi.org/10.1182/blood-2024-205727

Published: 2024

Journal Articles

Cardiac Monitoring of Patients on Btki for Chronic Lymphocytic Leukemia

Christine Gruessner, Alessandra Brofferio, Emily Tomasulo, Jeanine Superata, Shellin Jose, Susan Soto, Said Hafizullah Fayaz, Christopher Pleyer, Pia Nierman, Ovsanna Melikyan, Adrian Wiestner, Mark Haigney, Clare Sun

Blood (2024) 144 (Supplement 1): 6787.

https://doi.org/10.1182/blood-2024-205119

Published: 2024

Journal Articles

Activity and Safety of Venetoclax without Anti-CD20 Lead-in Therapy in Treatment Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

Christopher Pleyer, Emily Tomasulo, Jeanine Superata, Rachel Adams, Xin Tian, Jayson Grey, Pia Nierman, Adrian Wiestner, Clare Sun

Blood (2024) 144 (Supplement 1): 4620.

https://doi.org/10.1182/blood-2024-203506

Published: 2024

Journal Articles

T Cells from CLL Patients on Venetoclax Mount Potent Cytotoxic Responses in Combination with Epcoritamab, a CD20/CD3 Bispecific Antibody

Layla M. Saleh, Maissa Mhibik, Heribert Playà-Albinyana, Clare Sun, Christopher Pleyer, Adrian Wiestner

Blood (2024) 144 (Supplement 1): 3231.

https://doi.org/10.1182/blood-2024-198141

Published: 2024

Journal Articles

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Blood (2024) 144 (5): 510–524.

https://doi.org/10.1182/blood.2023021990

Published: 2024

Includes: Supplemental data

Journal Articles

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

Clare Sun, Raghuveer Mali, Rachel Kositsky, Xin Tian, Hannah Tomczak, Barrett Nuttall, Rafael White, Simon Rule, Veerendra Munugalavadla, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 1891.

https://doi.org/10.1182/blood-2023-178819

Published: 2023

Journal Articles

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Blood (2023) 142 (Supplement 1): 4463.

https://doi.org/10.1182/blood-2023-179872

Published: 2023

Journal Articles

Transcriptional Changes in Patients with CLL Starting Venetoclax Therapy Identifies Inflammatory and Adaptive Stress Responses

Layla M. Saleh, Maissa Mhibik, Jonathan Chen, Clare Sun, Christopher Pleyer, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 4196.

https://doi.org/10.1182/blood-2023-190376

Published: 2023

Journal Articles

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Andy Itsara, Clare Sun, Emily Bryer, Inhye E Ahn, Susan Soto, Hao-Wei Wang, Constance M. Yuan, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 201.

https://doi.org/10.1182/blood-2023-182397

Published: 2023

Journal Articles

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Blood (2023) 141 (13): 1584–1596.

https://doi.org/10.1182/blood.2022016934

Published: 2023

Includes: Supplemental data

Journal Articles

Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression

Clare Sun, Melih Acar, David Jenkins, Barrett Nuttall, Rafael White, Veerendra Munugalavadla, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 9847–9848.

https://doi.org/10.1182/blood-2022-159525

Published: 2022

Journal Articles

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Ziran Zhao, McKensie Collins, Clare Sun, Adrian Wiestner, J. Joseph Melenhorst

Blood (2022) 140 (Supplement 1): 10255–10256.

https://doi.org/10.1182/blood-2022-158614

Published: 2022

Journal Articles

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 2329–2332.

https://doi.org/10.1182/blood-2022-164772

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clonal architecture and growth dynamics of ibrutinib-resistant CLL: Oligoclonal BTK/PLCG2 mutations and emerging non-BTK/PLCG2 drivers

Role of the immune microenvironment in the clonal evolution of chronic lymphocytic leukemia

BTK inhibition drives mobilization and compartmental shifts of CLL subclones

Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies

Loss-of-function alterations in TRAF3 drive BTK/PLCG2-independent ibrutinib resistance in CLL

Venetoclax enhances T cell fitness and CAR T-cell manufacturing potential in chronic lymphocytic leukemia (CLL)

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells

Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK C481S -Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia

Cardiac Monitoring of Patients on Btki for Chronic Lymphocytic Leukemia

Activity and Safety of Venetoclax without Anti-CD20 Lead-in Therapy in Treatment Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

T Cells from CLL Patients on Venetoclax Mount Potent Cytotoxic Responses in Combination with Epcoritamab, a CD20/CD3 Bispecific Antibody

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Transcriptional Changes in Patients with CLL Starting Venetoclax Therapy Identifies Inflammatory and Adaptive Stress Responses

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only